Oncocyte Corp financial data

Symbol
OCX on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
15 Cushing, Irvine, California
State of incorporation
California
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 143 % -38.8%
Debt-to-equity 211 % +87.9%
Return On Equity -157 % -25.6%
Return On Assets -47.8 % +14.2%
Operating Margin -3.58K % -149%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.4M shares +62.2%
Common Stock, Shares, Outstanding 13.4M shares +62.2%
Entity Public Float 18.8M USD -72.6%
Common Stock, Value, Issued 326M USD +5.38%
Weighted Average Number of Shares Outstanding, Basic 12.9M shares +59.1%
Weighted Average Number of Shares Outstanding, Diluted 12.9M shares +59.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.02M USD -7.08%
Cost of Revenue 852K USD -17%
Research and Development Expense 9.35M USD +26.2%
Selling and Marketing Expense 2.99M USD +33.7%
General and Administrative Expense 9.32M USD -47.4%
Operating Income (Loss) -36.6M USD -132%
Nonoperating Income (Expense) 451K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -36.1M USD -123%
Net Income (Loss) Attributable to Parent -36.1M USD +39.4%
Earnings Per Share, Basic -4.57 USD/shares +62.9%
Earnings Per Share, Diluted -4.57 USD/shares +62.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.26M USD -46.7%
Accounts Receivable, after Allowance for Credit Loss, Current 85K USD -85.7%
Assets, Current 9.97M USD -52.5%
Property, Plant and Equipment, Net 5.58M USD -24.3%
Operating Lease, Right-of-Use Asset 4.04M USD +15.3%
Intangible Assets, Net (Excluding Goodwill) 56.6M USD -0.16%
Goodwill 18.7M USD +1.37%
Other Assets, Noncurrent 563K USD +71.1%
Assets 74.7M USD -14.6%
Accounts Payable, Current 1.05M USD +20.1%
Accrued Liabilities, Current 1.31M USD +0.62%
Liabilities, Current 7.2M USD -6.12%
Liabilities 52M USD +32.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 37K USD -9.76%
Retained Earnings (Accumulated Deficit) -304M USD -15.8%
Stockholders' Equity Attributable to Parent 22.7M USD -46.2%
Liabilities and Equity 74.7M USD -14.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.83M USD +53.9%
Net Cash Provided by (Used in) Financing Activities -28K USD +92.1%
Net Cash Provided by (Used in) Investing Activities -24K USD +98.3%
Common Stock, Shares Authorized 230M shares 0%
Common Stock, Shares, Issued 13.4M shares +62.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.85M USD +60.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.1M USD -59%
Interest Paid, Excluding Capitalized Interest, Operating Activities 13K USD -70.5%
Deferred Tax Assets, Valuation Allowance 67.3M USD +23.7%
Deferred Tax Assets, Gross 82.6M USD +15.1%
Operating Lease, Liability 3.04M USD
Depreciation 450K USD +56.8%
Payments to Acquire Property, Plant, and Equipment 24K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.1M USD +39.4%
Lessee, Operating Lease, Liability, to be Paid 3.58M USD -7.66%
Property, Plant and Equipment, Gross 8.84M USD +57.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.18M USD +36%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.14M USD +26.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 542K USD -32.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 695K USD -22.7%
Deferred Tax Assets, Operating Loss Carryforwards 61.8M USD +7.08%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 2.3M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 695K USD -22.7%
Operating Lease, Payments 272K USD -4.9%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 88K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 15.3M USD -11.8%
Share-based Payment Arrangement, Expense 1.9M USD -74.6%